FDA Clears SPECTRALIS Flex Module, Enhancing Advanced Ophthalmic Imaging for Underserved Patients
Heidelberg Engineering, a leading provider of ophthalmic imaging and healthcare data solutions, has announced that the FDA has granted clearance for its SPECTRALIS® Flex Module. This advanced, multimodal imaging platform…
Bausch + Lomb Gains FDA Approval for enVista Envy Intraocular Lens Offering Full Range of Vision
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global leader in eye health, has announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ intraocular lens (IOL). This…
Supergut Expands Nationwide at Target Amid Sales Surge
Supergut, the first clinically validated nutrition brand for gut health, is now available at Target stores across the U.S. and online at Target.com. The brand’s exclusive Target lineup features its…
MEDiC Life Sciences Partners with Hanmi on Cancer Biomarker Discovery, Secures Strategic Investment
MEDiC Life Sciences, a biotech startup based in Silicon Valley, has announced a new research collaboration with Hanmi Pharmaceutical, a prominent biopharmaceutical company in Korea. The partnership aims to identify…
Biogen’s Felzartamab Gains FDA Breakthrough Therapy Designation for Kidney Transplant Rejection
Biogen Inc. (Nasdaq: BIIB) – Biogen announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to felzartamab, an investigational anti-CD38 monoclonal antibody. This…
GSK Reports Positive Data for Arexvy RSV Vaccine, Showing Protection Over Three Seasons
GSK plc (LSE/NYSE: GSK) has announced new findings from the AReSVi-006 Phase III trial, which assessed the effectiveness of a single dose of Arexvy, a recombinant adjuvanted vaccine for respiratory…
Empowering the Veterinary Workforce by Broadening Educational Access
Veterinary technicians play a vital role in the veterinary field, carrying out important tasks such as assisting in surgeries, conducting diagnostic tests, and providing emergency care. To meet the increasing…
Gilead Shares New Efficacy, Safety, and Demographic Data from PURPOSE 2 Trial at HIV Research for Prevention Conference
Gilead Sciences, Inc. (Nasdaq: GILD) has released new data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), highlighting the efficacy and safety of lenacapavir, an injectable HIV-1 capsid inhibitor,…
Gilead to Showcase Antiviral Portfolio and HIV Innovations at IDWeek 2024
Gilead Sciences, Inc. has announced the presentation of new findings from its antiviral research and development programs at IDWeek 2024, scheduled for October 16-19. The presentations will include data from…
Results from Phase 3 TALAPRO-2 Trial Indicate TALZENNA and XTANDI Boost Overall Survival
Pfizer Inc. (NYSE: PFE) has announced encouraging topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study, evaluating TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)…
FDA Approves Pfizer’s HYMPAVZI for Hemophilia A and B Treatment
Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing bleeding episodes in adults…
Airsupra Reduces Risk of Severe Asthma Exacerbations in Phase III BATURA Trial
AstraZeneca’s Airsupra (albuterol/budesonide) has demonstrated promising outcomes in the BATURA Phase IIIb trial, achieving its primary endpoint by significantly and meaningfully reducing the risk of severe asthma exacerbations when used…